- Home
- VRCA vs RNTX Comparison
VRCA vs RNTX Comparison
Compare VRCA & RNTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRCA
- RNTX
- Stock Information
- Founded
- VRCA 2013
- RNTX 2001
- Country
- VRCA United States
- RNTX United States
- Employees
- VRCA N/A
- RNTX N/A
- Industry
- VRCA Biotechnology: Pharmaceutical Preparations
- RNTX Biotechnology: Pharmaceutical Preparations
- Sector
- VRCA Health Care
- RNTX Health Care
- Exchange
- VRCA Nasdaq
- RNTX Nasdaq
- Market Cap
- VRCA 32.7M
- RNTX 34.6M
- IPO Year
- VRCA 2018
- RNTX N/A
- Fundamental
- Price
- VRCA $4.54
- RNTX $1.25
- Analyst Decision
- VRCA Hold
- RNTX Buy
- Analyst Count
- VRCA 2
- RNTX 2
- Target Price
- VRCA N/A
- RNTX $10.00
- AVG Volume (30 Days)
- VRCA 93.9K
- RNTX 2.6M
- Earning Date
- VRCA 11-14-2025
- RNTX 11-14-2025
- Dividend Yield
- VRCA N/A
- RNTX N/A
- EPS Growth
- VRCA N/A
- RNTX N/A
- EPS
- VRCA N/A
- RNTX N/A
- Revenue
- VRCA $30,829,000.00
- RNTX N/A
- Revenue This Year
- VRCA $332.45
- RNTX N/A
- Revenue Next Year
- VRCA $12.85
- RNTX N/A
- P/E Ratio
- VRCA N/A
- RNTX N/A
- Revenue Growth
- VRCA 234.73
- RNTX N/A
- 52 Week Low
- VRCA $3.28
- RNTX $1.04
- 52 Week High
- VRCA $13.60
- RNTX $3.50
- Technical
- Relative Strength Index (RSI)
- VRCA 61.74
- RNTX 44.48
- Support Level
- VRCA $3.64
- RNTX $1.15
- Resistance Level
- VRCA $4.02
- RNTX $1.32
- Average True Range (ATR)
- VRCA 0.31
- RNTX 0.20
- MACD
- VRCA 0.10
- RNTX -0.04
- Stochastic Oscillator
- VRCA 92.28
- RNTX 11.65
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.
About RNTX Rein Therapeutics Inc. Common Stock
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.